Nanocarriers as nanomedicines: Design concepts and recent advances

Frontiers of Nanoscience

Volumn 4, Issue 1, 2012, Pages 337-440

  Grazú, Valeria ^a   Moros, María ^a   Sánchez Espinel, Christian ^b  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b NanoImmunoTech SL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DESIGN CONCEPT; NANOCARRIERS;

MEDICAL NANOTECHNOLOGY;

EID: 84872809037     PISSN: 18762778     EISSN: 1876276X     Source Type: Book Series    
DOI: 10.1016/B978-0-12-415769-9.00014-5     Document Type: Chapter

References (539)

1. Kaplun AP, Bezrukov DA, Shvets VI. Rational design of nano- and micro-size medicinal forms of biologically active substances. Appl Biochem Microbiol 2011;47:711-7.
2. Fernandez-Fernandez A, Manchanda R, McGoron AJ. Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol 2011;165:1628-51.
3. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. In: Schäfer-Korting M, editor. Drug delivery. Handbook of experimental pharmacology. Berlin: Springer; 2010.
4. Mahmood M, Casciano D, Xu Y, Biris AS. Engineered nanostructural materials for application in cancer biology and medicine. J Appl Toxicol 2012;32:10-9.
5. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011;8:2101-41.
6. Cavadas M, González-Fernández A, Franco R. Pathogen-mimetic stealth nanocarriers for drug delivery: a future possibility. Nanomedicine 2011;7:730-43.
7. Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv 2010; 7:479-95.
8. Yoo J-W, Doshi N, Mitragotri S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv Drug Deliv Rev 2011;63:1247-56. doi:10.1016/j.addr.2011.05.004.
9. Williams Y, et al. Comparison of three cell fixation methods for high content analysis assays utilizing quantum dots. J Microsc 2008;232:91-8.
10. França A, et al. Sterilization matters: consequences of different sterilization techniques on gold nanoparticles. Small 2010;6:89-95.
11. Cabral H, Nishiyama N, Kataoka K. Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc Chem Res 2011;44:999-1008.
12. Peer D, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60.
13. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010;9:615-27.
14. Markovsky E, et al. Administration, distribution, metabolism and elimination of polymerdrug conjugates. J Control Release 2011. doi:10.1016/j.jconrel.2011.12.021.
15. Calleja P, et al. Molecular buckets: cyclodextrins for oral cancer therapy. Ther Deliv 2012;3:43-57.
16. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012;64:557-70.
17. Wong TW. Design of oral insulin delivery systems. J Drug Target 2010;18:79-92.
18. Plapied L, Duhem N, des Rieux A, Préat V. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface Sci 2011;16:228-37.
19. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. Magnetic nanoparticles for drug delivery. Nano Today 2007;2:22-32.
20. Roger E, Lagarce F, Garcion E, Benoit J-P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond) 2010;5:287-306.
21. Fu J, Fiegel J, Krauland E, Hanes J. New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials 2002;23:4425-33.
22. Zhang J, Wu L, Chan H-K, Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev 2011;63:441-55.
23. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007;25:563-70.
24. Li M, Al-Jamal KT, Kostarelos K, Reineke J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano 2010;4:6303-17.
25. Markovsky E, et al. Administration, distribution, metabolism and elimination of polymerdrug conjugates. J Control Release 2011. doi:10.1016/j.jconrel.2011.12.021.
26. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev 2010;62:284-304.
27. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011;63:170-83.
28. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev 2011;63:456-69.
29. Brewer SH, Glomm WR, Johnson MC, Knag MK, Franzen S. Probing BSA binding to citrate-coated gold nanoparticles and surfaces. Langmuir 2005;21:9303-7.
30. Sperling RA, Parak WJ. Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. Philos Transact A Math Phys Eng Sci 2010;368:1333-83.
31. Lourenco C, Teixeira M, Simões S, Gaspar R. Steric stabilization of nanoparticles: size and surface properties. Int J Pharm 1996;138:1-12.
32. Gref R, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 1995;16:215-33.
33. Owens III DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307:93-102.
34. Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol 2010;28:181-8.
35. Li Y, Wang J, Wientjes MG, Au JL. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev 2012;64:29-39. doi:10.1016/ j.addr.2011.04.006.
36. Choi HS, et al. Renal clearance of quantum dots. Nat Biotechnol 2007;25:1165-70. 37. Choi HS, et al. Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol 2010;5:42-7.
37. Choi HS, et al. Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol 2010;5:42-7.
38. Li Y-F, Chen C. Fate and toxicity of metallic and metal-containing nanoparticles for biomedical applications. Small 2011;7:2965-80.
39. De Jong WH, et al. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008;29:1912-9.
40. Moghimi SM, Hunter A, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318.
41. Daum N, Tscheka C, Neumeyer A, Schneider M. Novel approaches for drug delivery systems in nanomedicine: effects of particle design and shape. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012;4:52-65.
42. Park J, et al. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 2009;5:694-700.
43. Lasagna-Reeves C, et al. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Commun 2010;393:649-55.
44. Hirn S, et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm 2011;77:407-16.
45. Phillips MA, Gran ML, Peppas NA. Targeted nanodelivery of drugs and diagnostics. Nano Today 2010;5:143-59.
46. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009;61:428-37.
47. Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv 2011;8:343-57.
48. Monopoli MP, et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 2011;133:2525-34.
49. Dell'Orco D, Lundqvist M, Oslakovic C, Cedervall T, Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One 2010;5:e10949.
50. Asuri P, Bale SS, Karajanagi SS, Kane RS. The protein-nanomaterial interface. Curr Opin Biotechnol 2006;17:562-8.
51. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell "sees" in bionanoscience. J Am Chem Soc 2010;132:5761-8.
52. Mahmoudi M, Serpooshan V. Large protein absorptions from small changes on the surface of nanoparticles. J Phys Chem C 2011;115:18275-83.
53. Dobrovolskaia MA, et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine 2009;5:106-17.
54. Lundqvist M, et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 2008;105: 14265-70.
55. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995;17:31-48.
56. Lipka J, et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 2010;31:1-8.
57. Karakoti AS, Das S, Thevuthasan S, Seal S. PEGylated inorganic nanoparticles. Angew Chem Int Ed Engl 2011;50:1980-94.
58. Choi SW, Kim WS, Kim JH. Surface modification of functional nanoparticles for controlled drug delivery. J Dispers Sci Technol 2003;24:475-87.
59. Moghimi S, Pavey K, Hunter A. Real-time evidence of surface modification at polystyrene lattices by poloxamine 908 in the presence of serum: in vivo conversion of macrophageprone nanoparticles to stealth entities by poloxamine 908. FEBS Lett 2003;547:177-82.
60. Laurent S, et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 2008;108: 2064-110.
61. Torchilin VP, Trubetskoy VS. Which polymers can make nanoparticulate drug carriers longcirculating? Adv Drug Deliv Rev 1995;16:141-55.
62. Arias JL, Reddy LH, Couvreur P Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system. Biomacromolecules 2011;12:97-104.
63. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1:297-315.
64. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003;42:463-78.
65. Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol 2011;22:492-501.
66. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-8.
67. Dufort S, Sancey L, Coll J-L. Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. Adv Drug Deliv Rev 2012;64:179-89. doi10.1016/j.addr.2011.09.009.
68. Li SD, Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release 2010;145:178-81.
69. Xie J, Xu C, Kohler N, Hou Y, Sun S. Controlled PEGylation of monodisperse Fe3O4 nanoparticles for reduced non-specific uptake by macrophage cells. Adv Mater 2007;19:3163-6.
70. Faure A-C, et al. Control of the in vivo biodistribution of hybrid nanoparticles with different poly(ethylene glycol) coatings. Small 2009;5:2565-75.
71. Kaminskas LM, et al. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly L-lysine dendrimers. Mol Pharm 2008;5:449-63.
72. Kaminskas LM, et al. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-L-lysine dendrimers. Mol Pharm 2009;6:1190-204.
73. Wang YS, et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002;54:547-70.
74. Reddy LH, Murthy RSR. Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2004;148:161-6.
75. Webster R, et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 2007;35:9-16.
76. Bendele A, Seely J, Richey C, Sennello G, Shopp G. Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 1998;42:152-7.
77. Barz M, Luxenhofer R, Zentel R, Vicent MJ. Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure-property relationships to better defined therapeutics. Polym Chem 2011;2:1900.
78. Huang X, Teng X, Chen D, Tang F, He J. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 2010;31:438-48.
79. Nielsen LE, Landel RF. Mechanical properties of polymers and composites. New York: Marcel Dekker, Inc.; 1994.
80. Doshi N, Zahr AS, Bhaskar S, Lahann J, Mitragotri S. Red blood cell-mimicking synthetic biomaterial particles. Proc Natl Acad Sci USA 2009;106, 21495-9
81. Kelly C, Jefferies C, Cryan S-A. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011;2011:727241.
82. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 2002;79:29-40.
83. Jiang H-L, et al. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials 2008;29:1931-9.
84. Singodia D, Verma A, Verma RK, Mishra PR. Investigations into an alternate approach to target mannose receptors on macrophages using 4-sulfated N-acetyl galactosamine more efficiently in comparison with mannose-decorated liposomes: an application in drug delivery. Nanomedicine 2012;8:468-77. doi10.1016/j.nano.2011.07.002.
85. Aouadi M, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009;458:1180-4.
86. Kim S-S, et al. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther 2010;18:993-1001.
87. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev 2006;86:279-367.
88. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 2004;84:869-901.
89. Pappenheimer J, Renkin E, Borrero LM. Filtration, diffusion and molecular sieving through peripheral capillary membranes. A contribution to the pore theory of capillary permeability. Am J Physiol 1951;167:13-46.
90. Gentile F, Ferrari M, Decuzzi P. The transport of nanoparticles in blood vessels: the effect of vessel permeability and blood rheology. Ann Biomed Eng 2008;36:254-61.
91. Agarwal A, et al. Nanoparticles as novel carrier for brain delivery: a review. Curr Pharm Des 2009;15:917-25.
92. Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 2012;64:640-65.
93. Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 2012;64:686-700.
94. Sweet DM, Kolhatkar RB, Ray A, Swaan P, Ghandehari H. Transepithelial transport of PEGylated anionic poly(amidoamine) dendrimers: implications for oral drug delivery. J Control Release 2009;138:78-85.
95. Sadekar S, Ghandehari H. Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. Adv Drug Deliv Rev 2012;64:571-88.
96. Predescu SA, Predescu DN, Malik AB. Molecular determinants of endothelial transcytosis and their role in endothelial permeability. AmJ Physiol Lung CellMol Physiol 2007;293:L823-L842.
97. Lin I-C, et al. Interaction of densely polymer-coated gold nanoparticles with epithelial Caco-2 monolayers. Biomacromolecules 2011;12:1339-48.
98. Decuzzi P, Pasqualini R, Arap W, Ferrari M. Intravascular delivery of particulate systems: does geometry really matter? Pharm Res 2009;26:235-43.
99. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007;7:803-15.
100. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995;108:2369-79.
101. Esser S, et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 1998;140:947-59.
102. Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci USA 2009;106:21264-9.
103. Chacko A-M, Hood ED, Zern BJ, Muzykantov VR. Targeted nanocarriers for imaging and therapy of vascular inflammation. Curr Opin Colloid Interface Sci 2011;16:215-27.
104. Simone E, Ding B-S, Muzykantov V. Targeted delivery of therapeutics to endothelium. Cell Tissue Res 2009;335:283-300.
105. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-51.
106. Heldin C-H, Rubin K, Pietras K, Ö stman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13.
107. Holback H, Yeo Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm Res 2011;28:1819-30.
108. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007;67:2729-35.
109. Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev 2011;63:623-39.
110. Rabinovitch M. Professional and non-professional phagocytes: an introduction. Trends Cell Biol 1995;5:85-7.
111. Conradt B. With a little help from your friends: cells don't die alone. Nat Cell Biol 2002;4: E139-E143.
112. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 2007;8:603-12.
113. Iversen T-G, Skotland T, Sandvig K. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today 2011;6:176-85.
114. Swanson JA. Shaping cups into phagosomes and macropinosomes. Nat Rev Mol Cell Biol 2008;9:639-49.
115. Chimini G, Chavrier P. Function of Rho family proteins in actin dynamics during phagocytosis and engulfment. Nat Cell Biol 2000;2:E191-E196.
116. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999;17:593-623.
117. Swanson JA, Watts C. Macropinocytosis. Trends Cell Biol 1995;5:424.
118. Lim JP, Gleeson PA. Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol Cell Biol 2011;89:836-43.
119. Kerr MC, Teasdale RD. Defining macropinocytosis. Traffic 2009;10:364-71.
120. Jones AT. Macropinocytosis: searching for an endocytic identity and role in the uptake of cell penetrating peptides. J Cell Mol Med 2007;11:670-84.
121. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003;422:37-44.
122. McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrinmediated endocytosis. Nat Rev Mol Cell Biol 2011;12:517-33.
123. Kirchhausen T. Clathrin. Annu Rev Biochem 2000;69:699-727.
124. Damke H. Dynamin and receptor-mediated endocytosis. FEBS Lett 1996;389:48-51.
125. Rappoport JZ. Focusing on clathrin-mediated endocytosis. Biochem J 2008;412:415-23.
126. Michel V, Bakovic M. Lipid rafts in health and disease. Biol Cell 2007;99:129-40.
127. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007;59:748-58.
128. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 2001;3:473-83.
129. Parton RG, Richards AA. Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. Traffic 2003;4:724-38.
130. Hayer A, et al. Caveolin-1 is ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation. J Cell Biol 2010;191:615-29.
131. Ortegren U, Aboulaich N, Ost A, Strålfors P. A new role for caveolae as metabolic platforms. Trends Endocrinol Metab 2007;18:344-9.
132. Harvey RD, Calaghan SC. Caveolae create local signalling domains through their distinct protein content, lipid profile and morphology. J Mol Cell Cardiol 2012;52:366-75.
133. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007;8: 185-94.
134. Bastiani M, Parton RG. Caveolae at a glance. J Cell Sci 2010;123:3831-6.
135. Frank PG, Pavlides S, Lisanti MP. Caveolae and transcytosis in endothelial cells: role in atherosclerosis. Cell Tissue Res 2009;335:41-7.
136. Oh P, et al. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol 2007;25:327-37.
137. Sandvig K, Torgersen ML, Raa HA, van Deurs B. Clathrin-independent endocytosis: from nonexisting to an extreme degree of complexity. Histochem Cell Biol 2008;129:267-76.
138. Hansen CG, Nichols BJ. Molecular mechanisms of clathrin-independent endocytosis. J Cell Sci 2009;122:1713-21.
139. Howes MT, Mayor S, Parton RG. Molecules, mechanisms, and cellular roles of clathrinindependent endocytosis. Curr Opin Cell Biol 2010;22:519-27.
140. Sandvig K, Pust S, Skotland T, van Deurs B. Clathrin-independent endocytosis: mechanisms and function. Curr Opin Cell Biol 2011;23:413-20.
141. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60.
142. Dutta D, Pulsipher A, Luo W, Mak H, Yousaf MN. Engineering cell surfaces via liposome fusion. Bioconjug Chem 2011;22:2423-33.
143. Xia T, Kovochich M, Liong M, Zink JI, Nel AE. Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways. ACSNano 2008;2:85-96.
144. Albanese A, Chan WCW. Effect of gold nanoparticle aggregation on cell uptake and toxicity. ACS Nano 2011;5:5478-89.
145. Dos Santos T, Varela J, Lynch I, Salvati A, Dawson KA. Quantitative assessment of the comparative nanoparticle-uptake efficiency of a range of cell lines. Small 2011;7:3341-9.
146. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009;66:2873-96.
147. Wang J, Byrne JD, Napier ME, DeSimone JM. More effective nanomedicines through particle design. Small 2011;7:1919-31. doi:10.1002/smll.201100442.
148. Verma A, et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater 2008;7:588-95.
149. Cai J, et al. Effect of chain length on cytotoxicity and endocytosis of cationic polymers. Macromolecules 2011;44:2050-7.
150. Qaddoumi MG, et al. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res 2004;21:641-8.
151. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004;377:159-69.
152. Chithrani BD, Chan WCW. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 2007;7:1542-50.
153. Wang Z, Tiruppathi C, Minshall RD, Malik AB. Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. ACS Nano 2009;3:4110-6.
154. Yoo J-W, Mitragotri S. Polymer particles that switch shape in response to a stimulus. Proc Natl Acad Sci USA 2010;107:11205-10.
155. Gratton SEA, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 2008;105:11613-8.
156. Chithrani BD, Ghazani AA, Chan WCW. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006;6:662-8.
157. Arvizo RR, et al. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett 2010;10:2543-8.
158. Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 2008;9:435-43.
159. Dausend J, et al. Uptake mechanism of oppositely charged fluorescent nanoparticles in HeLa cells. Macromol Biosci 2008;8:1135-43.
160. Cho EC, Xie J, Wurm PA, Xia Y. Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant. Nano Lett 2009;9:1080-4.
161. Harush-Frenkel O, Debotton N, Benita S, Altschuler Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Commun 2007;353:26-32.
162. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007;104:15549-54.
163. Moros M, et al. Monosaccharides versus PEG-functionalized NPs: influence in the cellular uptake. ACS Nano 2012;6:1565-77. doi:10.1021/nn204543c.
164. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008;41:120-9.
165. Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta 2011;1816:232-46.
166. Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 2005;62:1839-49.
167. Said Hassane F, Saleh aF, Abes R, Gait MJ, Lebleu B. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci 2010;67:715-26.
168. Järver P, Langel U. Cell-penetrating peptides-a brief introduction. Biochim Biophys Acta 2006;1758:260-3.
169. Madani F, Lindberg S, Langel U, Futaki S, Gräslund A. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys 2011;2011:414729.
170. Richard JP, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003;278:585-90.
171. Ziegler A. Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv Drug Deliv Rev 2008;60:580-97.
172. Trabulo S, Cardoso AL, Mano M, de Lima MCP. Cell-penetrating peptides-mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals 2010;3:961-93.
173. Endoh T, Ohtsuki T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev 2009;61:704-9.
174. Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009;61:953-64.
175. Caron NJ, Quenneville SP, Tremblay JP. Endosome disruption enhances the functional nuclear delivery of Tat-fusion proteins. Biochem Biophys Res Commun 2004;319:12-20.
176. de la Fuente JM, Berry CC. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug Chem 2005;16:1176-80.
177. Ruan G, Agrawal A, Marcus AI, Nie S. Imaging and tracking of tat peptide-conjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J Am Chem Soc 2007;129:14759-66.
178. Krpetić Z, et al. Negotiation of intracellular membrane barriers by TAT-modified gold nanoparticles. ACS Nano 2011;5:5195-201.
179. Oh E, et al. Cellular uptake and fate of PEGylated gold nanoparticles is dependent on both cell-penetration peptides and particle size. ACS Nano 2011;5:6434-48.
180. Wang H, Zhong C-Y, Wu J-F, Huang Y-B, Liu C-B. Enhancement of TAT cell membrane penetration efficiency by dimethyl sulphoxide. J Control Release 2010;143:64-70.
181. Ye S-F, et al. Synergistic effects of cell-penetrating peptide Tat and fusogenic peptide HA2- enhanced cellular internalization and gene transduction of organosilica nanoparticles. Nanomedicine 2011;2:1-9.
182. Abes S, et al. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 2006; 116:304-13.
183. Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J 2007;9:E18-E29.
184. Vive's E, Schmidt J, Pe'legrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 2008;1786:126-38.
185. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285:1569-72.
186. Song E, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23:709-17.
187. McNamara JO, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24:1005-15.
188. Kim KS, et al. Bioimaging for targeted delivery of hyaluronic acid derivatives to the livers in cirrhotic mice using quantum dots. ACS Nano 2010;4:3005-14.
189. Kao HP, Abney JR, Verkman A. Determinants of the translational mobility of a small solute in cell cytoplasm. J Cell Biol 1993;120:175-84.
190. Lechardeur D, Verkman AS, Lukacs GL. Intracellular routing of plasmid DNA during nonviral gene transfer. Adv Drug Deliv Rev 2005;57:755-67.
191. Wente SR. Gatekeepers of the nucleus. Science 2000;288:1374-7.
192. Wagstaff KM, Jans DA. Nuclear drug delivery to target tumour cells. Eur J Pharmacol 2009;625:174-80.
193. Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape pathways for delivery of biologicals. J Control Release 2011;151:220-8.
194. Boussif O, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995;92:7297-301.
195. Richardson SC, Pattrick NG, Man YK, Ferruti P, Duncan R. Poly(amidoamine)s as potential nonviral vectors: ability to form interpolyelectrolyte complexes and to mediate transfection in vitro. Biomacromolecules 2001;2:1023-8.
196. Cheung CY, Murthy N, Stayton PS, Hoffman AS. A pH-sensitive polymer that enhances cationic lipid-mediated gene transfer. Bioconjug Chem 2006;12:906-10.
197. Benns JM, Choi JS, Mahato RI, Park JS, Kim SW. pH-sensitive cationic polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) comb shaped polymer. Bioconjug Chem 2000;11:637-45.
198. Chang K-L, Higuchi Y, Kawakami S, Yamashita F, Hashida M. Efficient gene transfection by histidine-modified chitosan through enhancement of endosomal escape. Bioconjug Chem 2010;21:1087-95.
199. Huang JG, Leshuk T, Gu FX. Emerging nanomaterials for targeting subcellular organelles. Nano Today 2011;6:478-92.
200. Zelphati O, Szoka FC. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 1996;93:11493-8.
201. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008;29:3477-96.
202. Paillard A, Hindré F, Vignes-Colombeix C, Benoit J-P, Garcion E. The importance of endolysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials 2010;31:7542-54.
203. Mastrobattista E, et al. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem 2002;277:27135-43.
204. Li W, Nicol F, Szoka FC. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv Drug Deliv Rev 2004;56:967-85.
205. Wyman TB, et al. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 1997;36:3008-17.
206. Nakase I, Kobayashi S, Futaki S. Endosome-disruptive peptides for improving cytosolic delivery of bioactive macromolecules. Biopolymers 2010;94:763-70.
207. Selbo PK, et al. Photochemical internalization provides time- and space-controlled endolysosomal escape of therapeutic molecules. J Control Release 2010;148:2-12.
208. Zhou Z, et al. Charge-reversal drug conjugate for targeted cancer cell nuclear drug delivery. Adv Funct Mater 2009;19:3580-9.
209. Escoffre J-M, Teissié J, Rols M-P. Gene transfer: how can the biological barriers be overcome? J Membr Biol 2010;236:61-74.
210. Panté N, Kann M. Nuclear pore complex is able to transport macromolecules with diameters of 39 nm. Mol Biol Cell 2002;13:425-34.
211. Misra R, Sahoo SK. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci 2010;39:152-63.
212. Symens N, et al. Intracellular partitioning of cell organelles and extraneous nanoparticles during mitosis. Adv Drug Deliv Rev 2012;64:78-94. doi:10.1016/j.addr.2011.11.012.
213. Sui M, Liu W, Shen Y. Nuclear drug delivery for cancer chemotherapy. J Control Release 2011;155:227-36.
214. Pouton CW, Wagstaff KM, Roth DM, Moseley GW, Jans DA. Targeted delivery to the nucleus. Adv Drug Deliv Rev 2007;59:698-717.
215. Furumoto K, et al. Biliary excretion of polystyrene microspheres depends on the type of receptor-mediated uptake in rat liver. Biochim Biophys Acta 2001;1526:221-6.
216. Ballou B, et al. Sentinel lymph node imaging using quantum dots in mouse tumor models. Bioconjug Chem 2007;18:389-96.
217. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82.
218. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000;11(Suppl. 2):S81-S91.
219. Torchilin VP. Drug Delivery (Handbook of Experimental Pharmacology 197). Berlin Heidelberg: Springer-Verlag; 2010.
220. McBain SC, Yiu HHP, Dobson J. Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine 2008;3:169-80.
221. Prijic S, Sersa G. Magnetic nanoparticles as targeted delivery systems in oncology. Radiol Oncol 2011;45:1-16.
222. Sun C, Lee JSH, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008;60:1252-65.
223. Barakat NS. Magnetically modulated nanosystems: a unique drug-delivery platform. Nanomedicine 2009;4:799-812.
224. Nacev A, Beni C, Bruno O, Shapiro B. Magnetic nanoparticle transport within flowing blood and into surrounding tissue. Nanomedicine 2010;5:1459-66.
225. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009;3:16-20.
226. Hartner WC, Verma DD, Levchenko TS, Bernstein EA, Torchilin VP. ATP-loaded liposomes for treatment of myocardial ischemia. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009;1:530-9.
227. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41: 189-207.
228. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
229. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001;74:47-61.
230. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63:136-51.
231. Yuan F, Leunig M, Huang SK. Mirovascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994;54: 3352-6.
232. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011;63:131-5.
233. Jain KK. Advances in the field of nanooncology. BMC Med 2010;8:83.
234. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 2011;63:161-9.
235. Krasnici S, et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003;105:561-7.
236. Dass CR, Choong PFM. Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy. Cancer Cell Int 2006;6:17.
237. Lee H, Hoang B, Fonge H, Reilly RM, Allen C. In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels. Pharm Res 2010;27:2343-55.
238. Lee H, Fonge H, Hoang B, Reilly RM, Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm 2010;7:1195-208.
239. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6: 583-92.
240. Wong C, et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci USA 2011;108:2426-31.
241. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010;188:759-68.
242. Hobbs SK, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998;95:4607-12.
243. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010;7:653-64.
244. Chrastina A, Massey Ka, Schnitzer JE. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011;3:421-37.
245. Okuhata Y. Delivery of diagnostic agents for magnetic resonance imaging. Adv Drug Deliv Rev 1999;37:121-37.
246. Kirpotin DB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66:6732-40.
247. Kondo K, et al. Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis. Chest 1990;97:1367-71.
248. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006;121:144-58.
249. Daniels TR, et al. Transferrin receptors and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2012;1820:291-317.
250. Davis ME, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067-70.
251. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009;13:256-62.
252. Shia J, et al. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol 2008;39:498-505.
253. Parker N, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-93.
254. Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev 2008;27:655-64.
255. Zhang W, Tong L, Yang C. Cellular binding and internalization of functionalized silicon nanowires. Nano Lett 2012;12:1002-6. dx.doi.org/10.1021/nl204131n.
256. Kukowska-Latallo JF, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005;65:5317-24.
257. Wang X, et al. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 2011;5:6184-94.
258. McNeeley KM, Annapragada A, Bellamkonda RV. Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology 2007;18:385101.
259. Kawano K, Maitani Y. Effects of polyethylene glycol spacer length and ligand density on folate receptor targeting of liposomal Doxorubicin in vitro. J Drug Deliv 2011;2011:160967.
260. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 2003;92:49-67.
261. Ruiz NI, Drickamer K. Differential ligand binding by two subunits of the rat liver asialoglycoprotein receptor. Glycobiology 1996;6:551-9.
262. Mamidyala SK, et al. Glycomimetic ligands for the human asialoglycoprotein receptor. J Am Chem Soc 2012;134:1978-81.
263. Yang R, et al. Galactose-decorated cross-linked biodegradable poly(ethylene glycol)-b-poly (e-caprolactone) block copolymer micelles for enhanced hepatoma-targeting delivery of paclitaxel. Biomacromolecules 2011;12:3047-55.
264. Seymour LW, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002;20:1668-76.
265. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12:5268-72.
266. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7(Suppl. 4):31-9.
267. Sachdev JC, Jahanzeb M. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Clin Breast Cancer 2011;12:19-29.
268. Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Targeted therapies: how personal should we go? Nat Rev Clin Oncol 2011;9:87-97.
269. Mukohara T. Role of HER2-targeted agents in adjuvant treatment for breast cancer. Chemother Res Pract 2011;2011:730360.
270. Nielsen UB, et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002;1591:109-18.
271. Drummond DC, et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release 2010;141:13-21.
272. Gosk S, Moos T, Gottstein C, Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 2008;1778:854-63.
273. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
274. Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 2009;61:1177-88.
275. Wicki A, et al. Targeting_tumor-associated endothelial cells: anti-VEGFR2-immunoliposomes mediate tumor-vessel disruption and inhibit tumor growth. Clin Cancer Res 2012;18:454-64.
276. Linkous AG, Yazlovitskaya EM. Novel therapeutic approaches for targeting tumor angiogenesis. Anticancer Res 2012;32:1-12.
277. Jubeli E, Moine L, Vergnaud J, Barratt G. E-selectin as a target for drug delivery and molecular imaging. J Control Release 2011;158:194-206.
278. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008;60:1615-26.
279. Banerjee D, Harfouche R, Sengupta S. Nanotechnology-mediated targeting of tumor angiogenesis. Vasc Cell 2011;3:3.
280. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
281. Kim Y-H, et al. Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125. Small 2011;7:2052-60.
282. Sugahara KN, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009;16:510-20.
283. Sugahara KN, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010;328:1031-5.
284. Wang Z, Tiruppathi C, Cho J, Minshall RD, Malik AB. Delivery of nanoparticle: complexed drugs across the vascular endothelial barrier via caveolae. IUBMB Life 2011;63: 659-67.
285. Sahay G, Kim JO, Kabanov AV, Bronich TK. The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents. Biomaterials 2010;31:923-33.
286. Schnitzer JE. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am J Physiol Heart Circ Physiol 1992;262:H246-H254.
287. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60:876-85.
288. Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. J Control Release 2012. doi:10.1016/ j.jconrel.2011.11.028.
289. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 2011;153:198-205.
290. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 2001;53:321-39.
291. Mudshinge SR, Deore AB, Patil S, Bhalgat CM. Nanoparticles: emerging carriers for drug delivery. Saudi Pharm J 2011;19:129-41.
292. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 2008;126:187-204.
293. Kim J-H, Lee TR. Thermo- and pH-responsive hydrogel-coated gold nanoparticles. Chem Mater 2004;16:3647-51.
294. Sato K, Yoshida K, Takahashi S, Anzai J-I. pH- and sugar-sensitive layer-by-layer films and microcapsules for drug delivery. Adv Drug Deliv Rev 2011;63:809-21.
295. Bigall NC, et al. Magnetic nanocarriers with tunable pH dependence for controlled loading and release of cationic and anionic payloads. Adv Mater 2011;23:5645-50.
296. Kang KW, et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine 2010;6:210-3.
297. Luo Z, et al. Mesoporous silica nanoparticles end-capped with collagen: redox-responsive nanoreservoirs for targeted drug delivery. Angew Chem Int Ed Engl 2011;50:640-3.
298. de la Rica R, Aili D, Stevens MM. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Deliv Rev 2012. doi:10.1016/j.addr.2012.01.002.
299. Bae B-C, Na K. Development of polymeric cargo for delivery of photosensitizer in photodynamic therapy. Int J Photoenergy 2012;2012:431975.
300. Ge J, Neofytou E, Cahill TJ, Beygui RE, Zare RN. Drug release from electric-fieldresponsive nanoparticles. ACS Nano 2012;6:227-33.
301. Hawkins AM, Bottom CE, Liang Z, Puleo DA, Hilt JZ. Magnetic nanocomposite sol-gel systems for remote controlled drug release. Adv Healthc Mater 2012;1:96-100.
302. Loomis K, McNeeley K, Bellamkonda RV. Nanoparticles with targeting, triggered release, and imaging functionality for cancer applications. Soft Matter 2011;7:839.
303. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007;24:1029-46.
304. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
305. Goya GF, Grazu V, Ibarra MR. Magnetic nanoparticles for cancer therapy. Curr Nanosci 2008;4:16.
306. Abulateefeh SR, et al. Thermoresponsive polymer colloids for drug delivery and cancer therapy. Macromol Biosci 2011;11:1722-34.
307. Wei H, Cheng S-X, Zhang X-Z, Zhuo R-X. Thermo-sensitive polymeric micelles based on poly(N-isopropylacrylamide) as drug carriers. Prog Polym Sci 2009;34:893-910.
308. Chung JE, et al. Thermo-responsive drug delivery from polymeric micelles constructed using block copolymers of poly(N-isopropylacrylamide) and poly(butylmethacrylate). J Control Release 1999;62:115-27.
309. Liu B, et al. The antitumor effect of novel docetaxel-loaded thermosensitive micelles. Eur J Pharm Biopharm 2008;69:527-34.
310. Chung J, et al. Thermo-responsive drug delivery from polymeric micelles constructed using block copolymers of poly(N-isopropylacrylamide) and poly(butylmethacrylate). J Control Release 1999;62:115-27.
311. Gong W, et al. Improving efficiency of adriamycin crossing blood brain barrier by combination of thermosensitive liposomes and hyperthermia. Biol Pharm Bull 2011;34:1058-64.
312. Agarwal A, Mackey MA, El-Sayed MA, Bellamkonda RV. Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods. ACS Nano 2011;5:4919-26.
313. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000;60:1197-201.
314. Kong G, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000;60:6950.
315. Kono K, et al. Temperature sensitization of liposomes by use of thermosensitive block copolymers synthesized by living cationic polymerization: effect of copolymer chain length. Bioconjug Chem 2005;16:1367-74.
316. Chen W-H, Regen SL. Thermally gated liposomes. J Am Chem Soc 2005;127:6538-9.
317. Choi SH, Lee SH, Park TG. Temperature-sensitive pluronic/poly(ethylenimine) nanocapsules for thermally triggered disruption of intracellular endosomal compartment. Biomacromolecules 2006;7:1864-70.
318. Lee Y, Park SY, Kim C, Park TG. Thermally triggered intracellular explosion of volume transition nanogels for necrotic cell death. J Control Release 2009;135:89-95.
319. Tai L-A, et al. Thermosensitive liposomes entrapping iron oxide nanoparticles for controllable drug release. Nanotechnology 2009;20:135101.
320. Brazel CS. Magnetothermally-responsive nanomaterials: combining magnetic nanostructures and thermally-sensitive polymers for triggered drug release. Pharm Res 2009;26: 644-56.
321. Liu T-Y, et al. Instantaneous drug delivery of magnetic/thermally sensitive nanospheres by a high-frequency magnetic field. Langmuir 2008;24:13306-11.
322. Liu T-Y, Hu S-H, Liu D-M, Chen S-Y, Chen I-W. Biomedical nanoparticle carriers with combined thermal and magnetic responses. Nano Today 2009;4:52-65.
323. Liu T-Y, Liu K-H, Liu D-M, Chen S-Y, Chen I-W. Temperature-sensitive nanocapsules for controlled drug release caused by magnetically triggered structural disruption. Adv Funct Mater 2009;19:616-23.
324. McGill SL, Cuylear CL, Adolphi NL, Osiński M, Smyth HDC. Magnetically responsive nanoparticles for drug delivery applications using low magnetic field strengths. IEEE Trans Nanobioscience 2009;8:33-42.
325. Derfus AM, et al. Remotely triggered release from magnetic nanoparticles. Adv Mater 2007;19:3932-6.
326. Salmaso S, et al. Cell up-take control of gold nanoparticles functionalized with a thermoresponsive polymer. J Mater Chem 2009;19:1608.
327. Muñoz Javier A, et al. Photoactivated release of cargo from the cavity of polyelectrolyte capsules to the cytosol of cells. Langmuir 2008;24:12517-20.
328. Skirtach AG, et al. Laser-induced release of encapsulated materials inside living cells. Angew Chem Int Ed Engl 2006;45:4612-7.
329. Vivero-Escoto JL, Slowing II, Wu C-W, Lin VS-Y. Photoinduced intracellular controlled release drug delivery in human cells by gold-capped mesoporous silica nanosphere. J Am Chem Soc 2009;131:3462-3.
330. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989;49:4373-84.
331. Wu W, et al. Multi-functional core-shell hybrid nanogels for pH-dependent magnetic manipulation, fluorescent pH-sensing, and drug delivery. Biomaterials 2011;32:9876-87.
332. Murthy N, Campbell J, Fausto N, Hoffman AS, Stayton PS. Bioinspired pH-responsive polymers for the intracellular delivery of biomolecular drugs. Bioconjug Chem 2003;14: 412-9.
333. Kakizawa Y, Kataoka K. Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev 2002;54:203-22.
334. Kozlovskaya V, Sukhishvili SA. Amphoteric hydrogel capsules: multiple encapsulation and release routes. Macromolecules 2006;39:6191-9.
335. Lee ES, Kim D, Youn YS, Oh KT, Bae YH. A virus-mimetic nanogel vehicle. Angew Chem Int Ed Engl 2008;47:2418-21.
336. Chan Y, Wong T, Byrne F, Kavallaris M, Bulmus V. Acid-labile core cross-linked micelles for pH-triggered release of antitumor drugs. Biomacromolecules 2008;9:1826-36.
337. Qiao Z-Y, Zhang R, Du F-S, Liang D-H, Li Z-C. Multi-responsive nanogels containing motifs of ortho ester, oligo(ethylene glycol) and disulfide linkage as carriers of hydrophobic anti-cancer drugs. J Control Release 2011;152:57-66.
338. Ding C, Gu J, Qu X, Yang Z. Preparation of multifunctional drug carrier for tumor-specific uptake and enhanced intracellular delivery through the conjugation of weak acid labile linker. Bioconjug Chem 2009;20:1163-70.
339. Clawson C, et al. Synthesis and characterization of lipid-polymer hybrid nanoparticles with pH-triggered poly(ethylene glycol) shedding. Langmuir 2011;27:10556-61.
340. Yuan Z, et al. PEG-detachable and acid-labile cross-linked micelles based on orthoester linked graft copolymer for paclitaxel release. Nanotechnology 2011;22:335601.
341. Lavignac N, Nicholls JL, Ferruti P, Duncan R. Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker. Macromol Biosci 2009;9:480-7.
342. Kaminskas LM, et al. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. J Control Release 2011;152:241-8.
343. van der Poll DG, et al. Design, synthesis, and biological evaluation of a robust, biodegradable dendrimer. Bioconjug Chem 2010;21:764-73.
344. Lu C, Xing MMQ, Zhong W. Shell cross-linked and hepatocyte-targeting nanoparticles containing doxorubicin via acid-cleavable linkage. Nanomedicine 2011;7:80-7.
345. Kakudo T, et al. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 2004;43:5618-28.
346. Husseini GA, Pitt WG. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008;60:1137-52.
347. Deckers R, Moonen CTW. Ultrasound triggered, image guided, local drug delivery. J Control Release 2010;148:25-33.
348. Price RJ, Skyba DM, Kaul S, Skalak TC. Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. Circulation 1998;98:1264-7.
349. Liu Y, Miyoshi H, Nakamura M. Encapsulated ultrasound microbubbles: therapeutic application in drug/gene delivery. J Control Release 2006;114:89-99.
350. Nelson JL, Roeder BL, Carmen JC, Roloff F, Pitt WG. Ultrasonically activated chemotherapeutic drug delivery in a rat model. Cancer Res 2002;62:7280-3.
351. Myhr G, Moan J. Synergistic and tumour selective effects of chemotherapy and ultrasound treatment. Cancer Lett 2006;232:206-13.
352. Howard B, Gao Z, Lee S-W, Seo M-H, Rapoport N. Ultrasound-enhanced chemotherapy of drug-resistant breast cancer tumors by micellar-encapsulated paclitaxel. Am J Drug Deliv 2006;4:97-104.
353. Rapoport NY, Kennedy AM, Shea JE, Scaife CL, Nam K-H. Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles. J Control Release 2009;138:268-76.
354. Husseini GA, et al. Release of doxorubicin from unstabilized and stabilized micelles under the action of ultrasound. J Nanosci Nanotechnol 2007;7:1028.
355. Evjen TJ, Hagtvet E, Nilssen EA, Brandl M, Fossheim SL. Sonosensitive dioleoylphosphatidylethanolamine- containing liposomes with prolonged blood circulation time of doxorubicin. Eur J Pharm Sci 2011;43:318-24.
356. Hagtvet E, Evjen TJ, Olsen DR, Fossheim SL, Nilssen EA. Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice. J Drug Target 2011;19:701-8.
357. Ueno Y, et al. Combination of ultrasound and bubble liposome enhance the effect of doxorubicin and inhibit murine osteosarcoma growth. Cancer Biol Ther 2011;12:270-7.
358. Moon GD, et al. A new theranostic system based on gold nanocages and phase-change materials with unique features for photoacoustic imaging and controlled release. J Am Chem Soc 2011;133:4762-5.
359. Li W, et al. Gold nanocages covered with thermally-responsive polymers for controlled release by high-intensity focused ultrasound. Nanoscale 2011;3:1724-30.
360. Zhang Q, et al. Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography. Nanotechnology 2009;20:395102.
361. Cheng R, et al. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J Control Release 2011;152:2-12.
362. Liu J, et al. Redox-responsive polyphosphate nanosized assemblies: a smart drug delivery platform for cancer therapy. Biomacromolecules 2011;12:2407-15.
363. Wang Y-C, Wang F, Sun T-M, Wang J. Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells. Bioconjug Chem 2011;22:1939-45.
364. Ghosh S, Irvin K, Thayumanavan S. Tunable disassembly of micelles using a redox trigger. Langmuir 2007;23:7916-9.
365. Zhao M, et al. Redox-responsive nanocapsules for intracellular protein delivery. Biomaterials 2011;32:5223-30.
366. Chong S-F, et al. A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules. Biomaterials 2009;30:5178-86.
367. Sexton A, et al. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano 2009;3:3391-400.
368. Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 2004;58:39-46.
369. Navab M, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004;45:993-1007.
370. Harris ML, et al. Free radicals and other reactive oxygen metabolites in inflammatory bowel disease: cause, consequence or epiphenomenon? Pharmacol Ther 1992;53:375-408.
371. Khutoryanskiy VV, Tirelli N. Oxidation-responsiveness of nanomaterials for targeting inflammatory reactions. Pure Appl Chem 2008;80:1703-18.
372. Dhanasekaran SM, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
373. Werle B, et al. Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with nonsmall cell lung carcinoma. Cancer 2000;89:2282-91.
374. Liaudet-Coopman E, et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 2006;237:167-79.
375. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000;291:113-35.
376. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
377. Yang Y, et al. Enzyme-responsive multifunctional magnetic nanoparticles for tumor intracellular drug delivery and imaging. Chem Asian J 2011;6:1381-9.
378. Matsumura S, Aoki I, Saga T, Shiba K. A tumor-environment-responsive nanocarrier that evolves its surface properties upon sensing matrix metalloproteinase-2 and initiates agglomeration to enhance T2 relaxivity for magnetic resonance imaging. Mol Pharm 2011;8:1970-4.
379. Choi KY, et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 2011;5:8591-9.
380. Thomas M, et al. A galactosidase-responsive "trojan horse" for the selective targeting of folate receptor-positive tumor cells. ChemMedChem 2011;6:1006-10.
381. Bernardos A, et al. Enzyme-responsive intracellular controlled release using nanometric silica mesoporous supports capped with "saccharides" ACS Nano 2010;4:6353-68.
382. Morimoto N, Winnik FM, Akiyoshi K. Botryoidal assembly of cholesteryl-pullulan/poly(Nisopropylacrylamide) nanogels. Langmuir 2007;23:217-23.
383. Klaikherd A, Nagamani C, Thayumanavan S. Multi-stimuli sensitive amphiphilic block copolymer assemblies. J Am Chem Soc 2009;131:4830-8.
384. Li L, et al. Self-quenchable biofunctional nanoparticles of heparin-folate-photosensitizer conjugates for photodynamic therapy. Carbohydr Polym 2011;86:708-15.
385. Shi D, Matsusaki M, Kaneko T, Akashi M. Photo-cross-linking and cleavage induced reversible size change of bio-based nanoparticles. Macromolecules 2008;41:8167-72.
386. McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 2009;30:3986-95.
387. Terada T, Iwai M, Kawakami S, Yamashita F, Hashida M. Novel PEG-matrix metalloproteinase- 2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma- selective targeting. J Control Release 2006;111:333-42.
388. Mok H, Bae KH, Ahn C-H, Park TG. PEGylated and MMP-2 specifically dePEGylated quantum dots: comparative evaluation of cellular uptake. Langmuir 2009;25:1645-50.
389. Hwang DK, et al. Stop-flow lithography for the production of shape-evolving degradable microgel particles. J Am Chem Soc 2009;131:4499-504.
390. Yoo J-W, Mitragotri S. Polymer particles that switch shape in response to a stimulus. Proc Natl Acad Sci USA 2010;107:11205-10.
391. Murakami T, Tsuchida K. Recent advances in inorganic nanoparticle-based drug delivery systems. Mini Rev Med Chem 2008;8:175-83.
392. Yiu HHP. Engineering the multifunctional surface on magnetic nanoparticles for targeted biomedical applications: a chemical approach. Nanomedicine (Lond) 2011;6:1429-46.
393. Hostetler MJ, et al. Alkanethiolate gold cluster molecules with core diameters from 1.5 to 5.2 nm: core and monolayer properties as a function of core size. Langmuir 1998;14:17-30.
394. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 2010;62: 1064-79.
395. Huang H-C, Barua S, Sharma G, Dey SK, Rege K. Inorganic nanoparticles for cancer imaging and therapy. J Control Release 2011;155:344-57.
396. Xu C, Sun S. Superparamagnetic nanoparticles as targeted probes for diagnostic and therapeutic applications. Dalton Trans 2009;(29):5583-91. doi:10.1039/b900272n.
397. Sun C, et al. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 2008;4:372-9.
398. Thiesen B, Jordan A. Clinical applications of magnetic nanoparticles for hyperthermia. Int J Hyperthermia 2008;24:467-74.
399. Maier-Hauff K, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 2007;81:53-60.
400. Maier-Hauff K, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2011;103:317-24.
401. Maier-Hauff K, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 2007;81:53-60.
402. Kumar CSSR, Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv Drug Deliv Rev 2011;63:789-808.
403. O'Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett 2004;209:171-6.
404. Sardar R, Funston AM, Mulvaney P, Murray RW. Gold nanoparticles: past, present, and future. Langmuir 2009;25:13840-51.
405. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine (Lond) 2007;2:681-93.
406. Daniel M-C, Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantumsize- related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev 2004;104:293-346.
407. Sau TK, Rogach AL, Jäckel F, Klar TA, Feldmann J. Properties and applications of colloidal nonspherical noble metal nanoparticles. Adv Mater 2010;22:1805-25.
408. Melancon MP, Zhou M, Li C. Cancer theranostics with near-infrared light-activatable multimodal nanoparticles. Acc Chem Res 2011;44:947-56.
409. Rai P, et al. Development and applications of photo-triggered theranostic agents. Adv Drug Deliv Rev 2010;62:1094-124.
410. Bardhan R, Lal S, Joshi A, Halas NJ. Theranostic nanoshells: from probe design to imaging and treatment of cancer. Acc Chem Res 2011;44:936-46.
411. Park H, et al. Multifunctional nanoparticles for combined doxorubicin and photothermal treatments. ACS Nano 2009;3:2919-26.
412. Burton ER, Libutti SK. Targeting TNF-alpha for cancer therapy. J Biol 2009;8:85.
413. Libutti SK, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010;16:6139-49.
414. Yang X, Stein EW, Ashkenazi S, Wang LV. Nanoparticles for photoacoustic imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009;1:360-8.
415. Ku G, Wang LV. Deeply penetrating photoacoustic tomography in biological tissues enhanced with an optical contrast agent. Opt Lett 2005;30:507.
416. Song KH, Kim C, Cobley CM, Xia Y, Wang LV. Near-infrared gold nanocages as a new class of tracers for photoacoustic sentinel lymph node mapping on a rat model. Nano Lett 2009;9:183-8.
417. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 2004;49:N309-N315.
418. Perumal S, Hofmann A, Scholz N, Rühl E, Graf C. Kinetics study of the binding of multivalent ligands on size-selected gold nanoparticles. Langmuir 2011;27:4456-64.
419. Rana S, Bajaj A, Mout R, Rotello VM. Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev 2012;64:200-16. doi:10.1016/j.addr.
420. Li X, et al. Enhancement of cell recognition in vitro by dual-ligand cancer targeting gold nanoparticles. Biomaterials 2011;32:2540-5.
421. Tan A, et al. Quantum dots and carbon nanotubes in oncology: a review on emerging theranostic applications in nanomedicine. Nanomedicine (Lond) 2011;6:1101-14.
422. Alivisatos P. The use of nanocrystals in biological detection. Nat Biotechnol 2004;22:47-52.
423. Voura EB, Jaiswal JK, Mattoussi H, Simon SM. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med 2004;10:993-8.
424. Alivisatos AP, Gu W, Larabell C. Quantum dots as cellular probes. Annu Rev Biomed Eng 2005;7:55-76.
425. Klostranec JM, Chan WCW. Quantum dots in biological and biomedical research: recent progress and present challenges. Adv Mater 2006;18:1953-64.
426. Ghaderi S, Ramesh B, Seifalian AM. Fluorescence nanoparticles "quantum dots" as drug delivery system and their toxicity: a review. J Drug Target 2011;19:475-86.
427. Smith AM, Dave S, Nie S, True L, Gao X. Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev Mol Diagn 2006;6:231-44.
428. Diagaradjane P, et al. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res 2008;14:731-41.
429. Shao L, Gao Y, Yan F. Semiconductor quantum dots for biomedicial applications. Sensors 2011;11:11736-51.
430. Yezhelyev MV, Qi L, O'Reagan RM, Nie S, Gao X. Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J Am Chem Soc 2008;130:9006-12.
431. Wang Y, Chen L. Quantum dots, lighting up the research and development of nanomedicine. Nanomedicine 2011;7:385-402.
432. Gill R, Zayats M, Willner I. Semiconductor quantum dots for bioanalysis. Angew Chem Int Ed Engl 2008;47:7602-25.
433. Bagalkot V, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 2007;7:3065-70.
434. Biju V, Mundayoor S, Omkumar RV, Anas A, Ishikawa M. Bioconjugated quantum dots for cancer research: present status, prospects and remaining issues. Biotechnol Adv 2010;28: 199-213.
435. Shao L, Gao Y, Yan F. Semiconductor quantum dots for biomedicial applications. Sensors 2011;11:11736-51.
436. Li X, Xie QR, Zhang J, Xia W, Gu H. The packaging of siRNA within the mesoporous structure of silica nanoparticles. Biomaterials 2011;32:9546-56.
437. Giri S, Trewyn BG, Lin VSY. Mesoporous silica nanomaterial-based biotechnological and biomedical delivery systems. Nanomedicine (Lond) 2007;2:99-111.
438. Cheng K, Sun S. Recent advances in syntheses and therapeutic applications of multifunctional porous hollow nanoparticles. Nano Today 2010;5:183-96.
439. Kunzmann A, et al. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta 2011;1810:361-73.
440. Reiss P, Protie're M, Li L. Core/Shell semiconductor nanocrystals. Small 2009;5:154-68. 441. Templeton DM, Liu Y. Multiple roles of cadmium in cell death and survival. Chem Biol Interact 2010;188:267-75.
441. Templeton DM, Liu Y. Multiple roles of cadmium in cell death and survival. Chem Biol Interact 2010;188:267-75.
442. Vivero-Escoto JL, Huang Y-T. Inorganic-organic hybrid nanomaterials for therapeutic and diagnostic imaging applications. Int J Mol Sci 2011;12:3888-927.
443. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect 2006;114:165-72.
444. Choi AO, Cho SJ, Desbarats J, Lovrić J, Maysinger D. Quantum dot-induced cell death involves Fas upregulation and lipid peroxidation in human neuroblastoma cells. J Nanobiotechnol 2007;5:1.
445. Shiohara A, Hoshino A, Hanaki K-I, Suzuki K, Yamamoto K. On the cyto-toxicity caused by quantum dots. Microbiol Immunol 2004;48:669-75.
446. El-Ansary A, Al-Daihan S. On the toxicity of therapeutically used nanoparticles: an overview. J Toxicol 2009;2009:754810.
447. Sharma A, Madhunapantula SV, Robertson GP. Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol 2012;8:47-69.
448. Fischer HC, Liu L, Pang KS, Chan WCW. Pharmacokinetics of nanoscale quantum dots: in vivo distribution, sequestration, and clearance in the rat. Adv Funct Mater 2006;16: 1299-305.
449. Fadeel B, Garcia-Bennett AE. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev 2010;62:362-74.
450. Lee S, Yun H-S, Kim S-H. The comparative effects of mesoporous silica nanoparticles and colloidal silica on inflammation and apoptosis. Biomaterials 2011;32:9434-43.
451. Qiao R, Yang C, Gao M. Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications. J Mater Chem 2009;19:6274-93.
452. Tang M-F, Lei L, Guo S-R, Huang W-L. Recent progress in nanotechnology for cancer therapy. Chin J Cancer 2010;29:775-80.
453. Buyukhatipoglu K, Clyne AM. Superparamagnetic iron oxide nanoparticles change endothelial cell morphology and mechanics via reactive oxygen species formation. J Biomed Mater Res A 2011;96:186-95.
454. Li JJ, Hartono D, Ong C-N, Bay B-H, Yung L-YL. Autophagy and oxidative stress associated with gold nanoparticles. Biomaterials 2010;31:5996-6003.
455. Soenen SJ, et al. Cellular toxicity of inorganic nanoparticles: common aspects and guidelines for improved nanotoxicity evaluation. Nano Today 2011;6:446-65. doi:10.1016/j. nantod.2011.08.001.
456. Maherani B, Arab-Tehrany ER, Mozafari M, Gaiani C, Linder M. Liposomes: a review of manufacturing techniques and targeting strategies. Curr Nanosci 2011;7:436-52.
457. Chou LYT, Ming K, Chan WCW. Strategies for the intracellular delivery of nanoparticles. Chem Soc Rev 2011;40:233-45.
458. Guterres SS, Alves MP, Pohlmann AR. Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights 2007;2:147-57.
459. Alberts DS, et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Onc.). Gynecol Oncol 2008;108:90-4.
460. Maitani Y. PEGylated lipidic systems with prolonged circulation longevity for drug delivery in cancer therapeutics. J Drug Deliv Sci Technol 2011;21:27-34.
461. De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008;3:133-49.
462. Zolnik BS, González-Fernández A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology 2010;151:458-65.
463. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006;114:100-9.
464. Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 2007;59:164-82.
465. Szebeni J, Muggia F, Gabizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011;63:1020-30.
466. Bunjes H. Structural properties of solid lipid based colloidal drug delivery systems. Curr Opin Colloid Interface Sci 2011;16:411-5.
467. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.
468. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-72.
469. Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv 2011;8:1407-24.
470. Harms M, Müller-Goymann CC. Solid lipid nanoparticles for drug delivery. J Drug Deliv Sci Technol 2011;21:89-99.
471. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54: S131-S155.
472. Matalanis A, Jones OG, McClements DJ. Structured biopolymer-based delivery systems for encapsulation, protection, and release of lipophilic compounds. Food Hydrocolloids 2011;25:1865-80.
473. Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnol 2011;9:55.
474. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm 2008;364:298-327.
475. Semete B, et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine 2010;6:662-71.
476. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009;2:59-64.
477. Roco MC, Mirkin CA, Hersam MC. Nanotechnology research directions for societal needs in 2020. Retrospective and outlooks. Berlin and Boston: Springer; 2011.
478. Xiong X-B, Falamarzian A, Garg SM, Lavasanifar A. Engineering of amphiphilic block copolymers for polymeric micellar drug and gene delivery. J Control Release 2011;155: 261-8.
479. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev 1999;99:3181-98.
480. Kim S, Park K. Polymer micelles for drug delivery. In: Mahato RI, Narang AS, editors. Targeted delivery of small and macromolecular drugs. Boca Raton, FL: Taylor & Francis; 2010.
481. Moughton AO, Hillmyer MA, Lodge TP. Multicompartment block polymer micelles. Macromolecules 2012;45:2-19.
482. Huynh L, Neale C, Pome's R, Allen C. Computational approaches to the rational design of nanoemulsions, polymeric micelles, and dendrimers for drug delivery. Nanomedicine 2012;8:20-36.
483. Veronese F. PEGylated protein drugs: basic science and clinical applications (milestones in drug therapy). Basel, Switzerland: Birkhauser Verlag Press; 2009.
484. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6: 688-701.
485. Gaikwad D, et al. Polymer-drug conjugates: recent achievements. Res J Pharm Biol Chem Sci 2011;2:200-8.
486. Discher DE, et al. Emerging applications of polymersomes in delivery: from molecular dynamics to shrinkage of tumors. Prog Polym Sci 2007;32:838-57.
487. Ahmed F, et al. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J Control Release 2006;116:150-8.
488. Kim S-H, Shum HC, Kim JW, Cho J-C, Weitz DA. Multiple polymersomes for programmed release of multiple components. J Am Chem Soc 2011;133:15165-71.
489. Prakash Jain J, Yenet Ayen W, Kumar N. Self assembling polymers as polymersomes for drug delivery. Curr Pharm Des 2011;17:65-79.
490. Tanner P, et al. Polymeric vesicles: from drug carriers to nanoreactors and artificial organelles. Acc Chem Res 2011;44:1039-49.
491. Sosnik A, Carcaboso ÁM, Chiappetta DA. Polymeric nanocarriers: new endeavors for the optimization of the technological aspects of drugs. Recent Pat Biomed Eng 2008;1:43-59.
492. Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev 2002;5:82-5.
493. Müller RH, Keck CM. 20 Years drug nanocrystals-where are we, and where to go? Eur J Pharm Biopharm 2011;80:1-3.
494. Katteboinaa S, Chandrasekhar VSR, Balaji S. Drug nanocrystals: a novel formulation approach for poorly soluble drugs. Int J PharmTech Res 2009;1:682-94.
495. Müller RH, Shegokar R, Gohla S, Keck CM. Nanocrystals: production, cellular drug delivery, current and future products. In: Prokop A, editor. Intracellular delivery. Fundamental biomedical technologies. Netherlands: Springer; 2011;5:411-32.
496. Müller RH, Gohla S, Keck CM. State of the art of nanocrystals-special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 2011;78:1-9.
497. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004;113:151-70.
498. Medina SH, El-Sayed MEH. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev 2009;109:3141-57.
499. Klajnert B, Bryszewska M. Dendrimers: properties and applications. Acta Biochim Pol 2001;48:199-208.
500. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today 2010;15:171-85.
501. Padilla De Jesús OL, Ihre HR, Gagne L, Fréchet JMJ, Szoka FC. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem 2002;13:453-61.
502. Lee CC, et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci USA 2006;103:16649-54.
503. Jevprasesphant R, et al. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 2003;252:263-6.
504. Ziemba B, Matuszko G, Bryszewska M, Klajnert B. Influence of dendrimers on red blood cells. Cell Mol Biol Lett 2012;17:21-35.
505. Liu Z, Robinson JT, Tabakman SM, Yang K, Dai H. Carbon materials for drug delivery & cancer therapy. Mater Today 2011;14:316-23.
506. Vashist SK, et al. Delivery of drugs and biomolecules using carbon nanotubes. Carbon 2011;49:4077-97.
507. Liu Z, Sun X, Nakayama-Ratchford N, Dai H. Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano 2007;1:50-6.
508. Allen BL, et al. Mechanistic investigations of horseradish peroxidase-catalyzed degradation of single-walled carbon nanotubes. J Am Chem Soc 2009;131:17194-205.
509. Allen BL, et al. Biodegradation of single-walled carbon nanotubes through enzymatic catalysis. Nano Lett 2008;8:3899-903.
510. Kagan VE, et al. Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation. Nat Nanotechnol 2010;5:354-9.
511. Elhissi AMA, Ahmed W, Hassan IU, Dhanak VR, D'Emanuele A. Carbon nanotubes in cancer therapy and drug delivery. J Drug Deliv 2012;2012:837327.
512. Levi-Polyachenko NH, Merkel EJ, Jones BT, Carroll DL, Stewart IV JH. Rapid photothermal intracellular drug delivery using multiwalled carbon nanotubes. Mol Pharm 2009;6:1092-9.
513. Liu X, et al. Optimization of surface chemistry on single-walled carbon nanotubes for in vivo photothermal ablation of tumors. Biomaterials 2011;32:144-51.
514. Mashal A, et al. Toward carbon-nanotube-based theranostic agents for microwave detection and treatment of breast cancer: enhanced dielectric and heating response of tissue-mimicking materials. IEEE Trans Biomed Eng 2010;57:1831-4.
515. Gannon CJ, et al. Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer 2007;110:2654-65.
516. Zavaleta C, et al. Noninvasive Raman spectroscopy in living mice for evaluation of tumor targeting with carbon nanotubes. Nano Lett 2008;8:2800-5.
517. Welsher K, et al. A route to brightly fluorescent carbon nanotubes for near-infrared imaging in mice. Nat Nanotechnol 2009;4:773-80.
518. De la Zerda A, et al. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol 2008;3:557-62.
519. Kostarelos K, et al. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotechnol 2007;2:108-13.
520. Raffa V, Ciofani G, Vittorio O, Riggio C, Cuschieri A. Physicochemical properties affecting cellular uptake of carbon nanotubes. Nanomedicine (Lond) 2010;5:89-97.
521. Kostarelos K, Bianco A, Prato M. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat Nanotechnol 2009;4:627-33.
522. Rybak-Smith MJ, Sim RB. Complement activation by carbon nanotubes. Adv Drug Deliv Rev 2011;63:1031-41.
523. Aschberger K, et al. Review of carbon nanotubes toxicity and exposure-appraisal of human health risk assessment based on open literature. Crit Rev Toxicol 2010;40:759-90.
524. Liu Z, et al. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci USA 2008;105:1410-5.
525. Ding L, et al. Molecular characterization of the cytotoxic mechanism of multiwall carbon nanotubes and nano-onions on human skin fibroblast. Nano Lett 2005;5:2448-64.
526. Pulskamp K, Diabaté S, Krug HF. Carbon nanotubes show no sign of acute toxicity but induce intracellular reactive oxygen species in dependence on contaminants. Toxicol Lett 2007;168:58-74.
527. Bottini M, Rosato N, Bottini N. PEG-modified carbon nanotubes in biomedicine: current status and challenges ahead. Biomacromolecules 2011;12:3381-93.
528. Fagan JA, et al. Carbon nanotubes: measuring dispersion and length. Adv Mater 2011;23:338-48.
529. Ghosh S, Bachilo SM, Weisman RB. Advanced sorting of single-walled carbon nanotubes by nonlinear density-gradient ultracentrifugation. Nat Nanotechnol 2010;5:443-50.
530. Hersam MC. Progress towards monodisperse single-walled carbon nanotubes. Nat Nanotechnol 2008;3:387-94.
531. Choi WI, et al. Tumor regression in vivo by photothermal therapy based on gold-nanorodloaded, functional nanocarriers. ACS Nano 2011;5:1995-2003.
532. Vallet-Regí M, Colilla M, González B. Medical applications of organic-inorganic hybrid materials within the field of silica-based bioceramics. Chem Soc Rev 2011;40:596-607.
533. Sanchez C, Belleville P, Popall M, Nicole L. Applications of advanced hybrid organic-inorganic nanomaterials: from laboratory to market. Chem Soc Rev 2011;40:696-753.
534. Ali Z, et al. Multifunctional nanoparticles for dual imaging. Anal Chem 2011;83:2877-82. 535. Cientifica's report, Nanotechnology in Drug Delivery 2011-2021: Global Market for Nanocarriers.
535. Cientifica's report, Nanotechnology in Drug Delivery 2011-2021: Global Market for Nanocarriers.
536. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009; 8:959-68.
537. Paul SM, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9:203-14.
538. Costantino L, Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov Today 2012;17:367-78. doi:10.1016/j.drudis. 2011.10.028.
539. Zhang L, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008;83:761-9.